Pricing Log in Create free account

ARS Pharmaceuticals, Inc. (SPRY) vs Zura Bio Limited (ZURA)

ARS Pharmaceuticals, Inc. and Zura Bio Limited are both Biotechnology companies. ARS Pharmaceuticals, Inc. and Zura Bio Limited are of similar size ($410.2M and $404.8M). Zura Bio Limited has the higher net margin (0.00% vs −184.3%) and the higher return on invested capital (0.00% vs −335.7%). Across the 13 metrics below, Zura Bio Limited leads on 12 and ARS Pharmaceuticals, Inc. on 1.

Valuation

Metric SPRY ZURA Biotechnology median
P/E n/m n/m 8.50
P/S 3.37 n/m 9.71
P/B 31.51 2.50 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 3.61 n/m 9.21
Earnings yield (54.91%) (29.05%) (33.15%)
Free cash flow yield (53.80%) (16.75%) (25.50%)

Profitability

Metric SPRY ZURA Biotechnology median
Gross margin 71.37% — 65.16%
Operating margin (184.96%) 0.00% 0.00%
Net margin (184.26%) 0.00% 0.00%
Free cash flow margin (167.97%) 0.00% 0.00%
Return on equity (210.37%) (71.76%) (56.36%)
Return on assets (76.54%) (62.74%) (48.04%)
Return on invested capital (335.65%) 0.00% 0.00%

Growth

Metric SPRY ZURA Biotechnology median
Revenue growth (TTM) 4.08% — 6.02%
EPS growth (last fiscal year) (2,275.00%) (76.67%) 30.26%
Revenue growth, 5-year CAGR — — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric SPRY ZURA Biotechnology median
Debt to equity 13.72 0.00 0.00
Current ratio 3.48 12.90 4.72
Net debt to EBITDA 0.42 1.45 0.96

Dividend

Metric SPRY ZURA Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric SPRY ZURA Biotechnology median
Market cap 404.75m 410.15m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack